News

News 31.08.2024 August 29, 2024. ZURICH, Switzerland and Newton, Massachusetts, US. — GlobeNewswire — Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids. NULISA is a proprietary high-sensitivity proteomics platform developed by...

News 28.08.2024 Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian has joined the Company as VP Commercial Strategy. Alex Bastian is an experienced commercial leader in the biotech...

News 27.08.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited...

News 20.08.2024 August 19, 2024 - Zurich, Switzerland, Brussels, Belgium, and New York, US InSphero, a leading innovator in 3D Cell Culture and Organ-on-Chip technology, has announced a new collaboration with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Université Libre de Bruxelles (ULB) Center for Diabetes Research. With funding from...

News 08.08.2024 Schlieren (Zurich), Switzerland, August 8, 2024 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced financial results for the first half of 2024. Revenue from direct MagnetOs product sales were CHF 31.6 million compared to CHF 12.2 million in H1 2023.  Total revenue...